Y Combinator• Apr 6, 2026• 20:40Interview

BillionToOne Is Solving One of Biotech’s Hardest Problems

From Y Combinator

Y Combinator

Executive Summary

Billion to One has developed a novel molecular diagnostics platform that reduces noise in DNA sequencing, enabling the detection of rare genetic material in blood samples.
The company successfully commercialized this technology first in the prenatal testing market, capturing nearly 20% market share and achieving profitability.
Leveraging its core technology and revenue from prenatal testing, Billion to One is executing a phased expansion into oncology, targeting minimal residual disease (MRD) and ultimately early-stage cancer screening.
The company's journey from a two-person startup to a profitable, $4B+ public company highlights a successful strategy of pairing deep-tech innovation with a pragmatic, staged go-to-market approach.

12 quotes

Concerns Raised

The scientific and clinical validation hurdles for early-stage cancer screening are exceptionally high and will require significant time and resources.
Competition in the liquid biopsy and oncology diagnostics space is intense, with many well-funded players.
Maintaining an innovative, fast-moving startup culture post-IPO as the company scales can be challenging.

Opportunities Identified

Capturing a significant share of the multi-billion dollar minimal residual disease (MRD) testing market for post-surgery cancer patients.
The ultimate 'holy grail' opportunity of developing a widely adopted blood test for early-stage cancer screening in the general population.
Continued market share growth in the global prenatal genetic testing market.

Key Themes

Platform Technology for Diagnostics

Billion to One's core innovation is a method to reduce the noise inherent in DNA amplification by adding synthetic DNA molecules to samples. This platform technology is not limited to one application; it was first proven in prenatal testing and is now being applied to the more complex field of oncology, demonstrating its versatility.

This signifies a strong technological moat and creates multiple large addressable markets for the company, de-risking its long-term growth from reliance on a single product.

Phased Go-to-Market Strategy

The company deliberately chose to enter the prenatal market first, as it was a more capital-efficient and faster path to commercialization. The revenue and operational expertise gained from this initial market are now funding the more ambitious and resource-intensive push into late-stage and early-stage cancer detection.

This strategic sequencing, analogous to Tesla's master plan, provides a powerful blueprint for deep-tech companies to tackle 'holy grail' problems without requiring massive, speculative upfront capital.

Solving the 'Needle in a Haystack' Problem

The fundamental challenge in liquid biopsies is detecting a few fragments of fetal or tumor DNA among billions of other molecules. Billion to One's technology quantifies and computationally removes the errors introduced during the necessary amplification step, dramatically improving the signal-to-noise ratio and enabling detection of previously invisible genetic markers.

This technical breakthrough is the key enabler for their entire product portfolio, giving them a performance edge in sensitivity and accuracy over traditional methods.

Scaling from Lab to Public Company

The company's story traces a rapid ascent from a shared lab bench and a difficult $300k seed round to a state-of-the-art, highly automated facility processing over 600,000 tests annually. This journey involved overcoming early sales challenges, scaling operations with AI and robotics, and ultimately achieving a successful IPO and profitability.

This demonstrates strong execution not just in science but also in operations, sales, and finance, which are critical for translating a scientific discovery into a sustainable, high-growth business.

Interdisciplinary R&D Culture

Billion to One's innovation was born from founders who bridged the gap between wet-lab chemistry and bioinformatics. This ethos is embedded in their R&D structure, which favors small, autonomous teams led by 'interdisciplinary people' who can manage a product's development end-to-end, accelerating iteration cycles.

This organizational design is a key competitive advantage, fostering rapid innovation and preventing the bureaucratic slowdowns that can plague larger R&D organizations.

Get started free

Topics

Billion to One Liquid Biopsy Genetic Testing Molecular Diagnostics Prenatal Diagnostics Oncology Cancer Detection Minimal Residual Disease (MRD)Cell-Free DNA (cfDNA)DNA Sequencing Go-to-Market Strategy Healthcare Technology Y Combinator Lab Automation Bioinformatics

Processed Apr 15, 2026 yt-dlp + mlx-whisper + Gemini